Trial Profile
A Pharmacokinetic Phase I study Comparing Docecal and Taxotere in Patients with Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics; Registrational
- Sponsors Vivesto
- 31 May 2020 Results assessing PK, safety and early activity from two clinical studies: EudraCT2012-005161-12 and EudraCT2013-004889-33 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 24 Jun 2019 According to an Oasmia Pharmaceutical media release, this study indicates that Docecal is bioequivalent with Taxotere (AUC0-last and Cmax) with regards to the total fraction of docetaxel in plasma.
- 24 Jun 2019 Results from the two clinical studies using Docecal in patients with metastatic breast cancer (CTP 293315 and CTP 293313) presented in an Oasmia Pharmaceutical media release.